Trials / Completed
CompletedNCT00653172
Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia
A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- Novexel Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXL103 | 600mg orally twice daily |
| DRUG | comparator | comparator twice daily |
| DRUG | NXL103 | 500mg orally twice daily |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-06-01
- Completion
- 2008-11-01
- First posted
- 2008-04-04
- Last updated
- 2009-01-09
Locations
60 sites across 9 countries: Chile, Croatia, Estonia, Germany, Peru, Poland, Romania, South Africa, Ukraine
Source: ClinicalTrials.gov record NCT00653172. Inclusion in this directory is not an endorsement.